Digest Network Come funziona
Network
/
Società
At
Non verificato

Atara Biotherapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

26 comunicati stampa

Guarda tutti i comunicati
12/11/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Mercato azionario
Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress
Fonte
Atara Biotherapeutics, Inc.
Emittente
Business Wire
1.00
0
03/09/2025
Biotecnologia
Salute
Farmaceutica
Oncologia
Mercato del lavoro
Atara Biotherapeutics Announces Changes to Its Board of Directors
Fonte
Atara Biotherapeutics, Inc.
Emittente
Business Wire
1.00
0
11/08/2025
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Mercato azionario
Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress
Fonte
Atara Biotherapeutics, Inc.
Emittente
Business Wire
1.00
0
24/07/2025
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Oncologia
Industria
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
Fonte
Atara Biotherapeutics, Inc.
Emittente
Business Wire
1.00
0
14/07/2025
Scienza
HIV, AIDS e malattie autoimmuni
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Oncologia
Industria
Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)
Fonte
Atara Biotherapeutics, Inc.
Emittente
Business Wire
1.00
0
17/05/2025
Mercato del lavoro
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors
Fonte
Atara Biotherapeutics, Inc.
Emittente
Business Wire
1.00
0
15/05/2025
Finanza
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress
Fonte
Atara Biotherapeutics, Inc.
Emittente
Business Wire
1.00
0
15/05/2025
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Oncologia
Atara Biotherapeutics Announces Pricing of $16 Million Offering
Fonte
Atara Biotherapeutics, Inc.
Emittente
Business Wire
1.00
0
05/05/2025
Industria
Oncologia
Salute
Igiene alimentare
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Farmaceutica
Biotecnologia
Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)
Fonte
Atara Biotherapeutics, Inc.
Emittente
Business Wire
1.00
0
07/03/2025
Mercato azionario
Scienza
Biologia
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress
Fonte
Atara Biotherapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0